Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements

Daniel Walden, Cody Eslinger, Tanios Bekaii-Saab

Research output: Contribution to journalReview articlepeer-review

Abstract

Biliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to roughly 1 year and is associated with a significant adverse event profile. Recently, advancements in genetic sequencing have opened new avenues of targeted treatment. In cholangiocarcinoma, FGFR2 alterations have been shown to be present in roughly 10–15% of intrahepatic cholangiocarcinoma. Pemigatinib, a FGFR1–4 inhibitor, has been shown to significantly extend survival in the second-line setting to over 20 months in patients who harbor FGFR2 fusions. Here, we outline the development and future direction of pemigatinib and other FGFR2 inhibitors in the field of advanced biliary tract cancers.

Original languageEnglish (US)
JournalTherapeutic Advances in Gastroenterology
Volume15
DOIs
StatePublished - 2022

Keywords

  • cholangiocarcinoma
  • FGFR
  • FGFR inhibitor
  • fusion
  • pemigatinib

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements'. Together they form a unique fingerprint.

Cite this